Yahoo! Finance: Biotechnology Industry News: Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate (ADC) Collaborator Data at ASCO Annual Meeting

Yahoo! Finance: Biotechnology Industry News The latest news on the Biotechnology industry from Yahoo! Finance

Seattle Genetics Highlights ADCETRIS® (Brentuximab Vedotin) Frontline HL and MTCL Clinical Development Programs and Antibody-Drug Conjugate (ADC) Collaborator Data at ASCO Annual Meeting Jun 2nd 2013, 13:00 [Business Wire] - Seattle Genetics, Inc. today highlighted ongoing clinical development programs for ADCETRIS in frontline Hodgkin lymphoma and mature T-cell lymphoma and progress with collaborator antibody-drug conjugate programs that were presented at the 49th Annual Meeting of the American Society of Clinical Oncology being held May 31 – June 4, 2013, in Chicago, IL.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions